Published in Mol Cell Neurosci on February 20, 2008
c-Jun reprograms Schwann cells of injured nerves to generate a repair cell essential for regeneration. Neuron (2012) 2.45
Schwann Cells: Development and Role in Nerve Repair. Cold Spring Harb Perspect Biol (2015) 1.16
Schwann cell dedifferentiation is independent of mitogenic signaling and uncoupled to proliferation: role of cAMP and JNK in the maintenance of the differentiated state. J Biol Chem (2010) 1.15
Repair of the Peripheral Nerve-Remyelination that Works. Brain Sci (2013) 0.94
Axonal outgrowth is associated with increased ERK 1/2 activation but decreased caspase 3 linked cell death in Schwann cells after immediate nerve repair in rats. BMC Neurosci (2011) 0.90
Merlin controls the repair capacity of Schwann cells after injury by regulating Hippo/YAP activity. J Cell Biol (2017) 0.90
An in-vitro traumatic model to evaluate the response of myelinated cultures to sustained hydrostatic compression injury. J Neurotrauma (2009) 0.86
Role of Schwann cells in the regeneration of penile and peripheral nerves. Asian J Androl (2015) 0.86
Mitogen Activated Protein Kinase Family Proteins and c-jun Signaling in Injury-induced Schwann Cell Plasticity. Exp Neurobiol (2014) 0.86
Visualizing peripheral nerve regeneration by whole mount staining. PLoS One (2015) 0.80
The RNA-binding protein human antigen R controls global changes in gene expression during Schwann cell development. J Neurosci (2012) 0.80
Methylcobalamin promotes the differentiation of Schwann cells and remyelination in lysophosphatidylcholine-induced demyelination of the rat sciatic nerve. Front Cell Neurosci (2015) 0.79
STAT3 Controls the Long-Term Survival and Phenotype of Repair Schwann Cells during Nerve Regeneration. J Neurosci (2017) 0.79
Cdc42 regulates Schwann cell radial sorting and myelin sheath folding through NF2/merlin-dependent and independent signaling. Glia (2013) 0.78
Axon degeneration: make the Schwann cell great again. Neural Regen Res (2017) 0.76
Gender differences in nerve regeneration after sciatic nerve injury and repair in healthy and in type 2 diabetic Goto-Kakizaki rats. BMC Neurosci (2014) 0.76
The Glia Response after Peripheral Nerve Injury: A Comparison between Schwann Cells and Olfactory Ensheathing Cells and Their Uses for Neural Regenerative Therapies. Int J Mol Sci (2017) 0.75
17β-Estradiol Promotes Schwann Cell Proliferation and Differentiation, Accelerating Early Remyelination in a Mouse Peripheral Nerve Injury Model. Biomed Res Int (2016) 0.75
After Nerve Injury, Lineage Tracing Shows That Myelin and Remak Schwann Cells Elongate Extensively and Branch to Form Repair Schwann Cells, Which Shorten Radically on Remyelination. J Neurosci (2017) 0.75
Involvement of upregulated SYF2 in Schwann cell differentiation and migration after sciatic nerve crush. Cell Mol Neurobiol (2014) 0.75
Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell (1995) 6.08
Induction of apoptosis by the low-affinity NGF receptor. Science (1993) 3.04
Peripheral nerve regeneration. Annu Rev Neurosci (1990) 2.77
Quantitative histology of Wallerian degeneration: II. Nuclear population in two nerves of different fibre spectrum. J Anat (1948) 2.36
Induction of cell death by endogenous nerve growth factor through its p75 receptor. Nature (1996) 2.28
Death of oligodendrocytes mediated by the interaction of nerve growth factor with its receptor p75. Nature (1996) 2.14
Neu differentiation factor is a neuron-glia signal and regulates survival, proliferation, and maturation of rat Schwann cell precursors. Neuron (1995) 2.02
Denervated Schwann cells attract macrophages by secretion of leukemia inhibitory factor (LIF) and monocyte chemoattractant protein-1 in a process regulated by interleukin-6 and LIF. J Neurosci (2002) 1.88
Axonal interactions regulate Schwann cell apoptosis in developing peripheral nerve: neuregulin receptors and the role of neuregulins. J Neurosci (1996) 1.71
Genome digestion is a dispensable consequence of physiological cell death mediated by cytotoxic T lymphocytes. Mol Cell Biol (1992) 1.71
Differential regulation of mRNA encoding nerve growth factor and its receptor in rat sciatic nerve during development, degeneration, and regeneration: role of macrophages. Proc Natl Acad Sci U S A (1987) 1.70
Ninjurin, a novel adhesion molecule, is induced by nerve injury and promotes axonal growth. Neuron (1996) 1.67
Functional indices for sciatic, peroneal, and posterior tibial nerve lesions in the mouse. Microsurgery (1998) 1.60
The fate of Schwann cells isolated from axonal contact. J Neurocytol (1978) 1.54
Motor axons preferentially reinnervate motor pathways. J Neurosci (1993) 1.47
Microanatomy of axon/glial signaling during Wallerian degeneration. J Neurosci (2005) 1.46
Monocyte chemoattractant protein 1 is responsible for macrophage recruitment following injury to sciatic nerve. J Neurosci Res (1998) 1.37
Loss of glial fibrillary acidic protein (GFAP) impairs Schwann cell proliferation and delays nerve regeneration after damage. J Cell Sci (2006) 1.37
Expression and functional roles of neural cell surface molecules and extracellular matrix components during development and regeneration of peripheral nerves. J Neurocytol (1994) 1.36
Cell death in the Schwann cell lineage and its regulation by neuregulin. Proc Natl Acad Sci U S A (1996) 1.31
Major changes in the expression of the mRNAs for cholinergic differentiation factor/leukemia inhibitory factor and its receptor after injury to adult peripheral nerves and ganglia. Proc Natl Acad Sci U S A (1994) 1.28
The p75 nerve growth factor receptor mediates survival or death depending on the stage of sensory neuron development. Proc Natl Acad Sci U S A (1994) 1.28
Developing Schwann cells acquire the ability to survive without axons by establishing an autocrine circuit involving insulin-like growth factor, neurotrophin-3, and platelet-derived growth factor-BB. J Neurosci (1999) 1.25
The chemokine receptor CCR2 is involved in macrophage recruitment to the injured peripheral nervous system. J Neuroimmunol (2000) 1.19
Induction of postnatal schwann cell death by the low-affinity neurotrophin receptor in vitro and after axotomy. J Neurosci (2000) 1.15
Interleukin-6 production by Schwann cells and induction in sciatic nerve injury. J Neurochem (1995) 1.13
A developmentally regulated switch directs regenerative growth of Schwann cells through cyclin D1. Neuron (2000) 1.07
Schwann cell mitosis in response to regenerating peripheral axons in vivo. Brain Res (1985) 1.04
The protein kinase inhibitor staurosporine induces morphological changes typical of apoptosis in MOLT-4 cells without concomitant DNA fragmentation. Biochem Biophys Res Commun (1993) 1.03
Schwann cell surfaces but not extracellular matrix organized by Schwann cells support neurite outgrowth from embryonic rat retina. J Neurosci (1988) 1.01
Degeneration of myelinated efferent fibers prompts mitosis in Remak Schwann cells of uninjured C-fiber afferents. J Neurosci (2005) 1.01
Control of Schwann cell survival and proliferation: autocrine factors and neuregulins. Mol Cell Neurosci (1998) 1.00
Myelin sheath remodelling in regenerated rat sciatic nerve. Brain Res (1985) 0.98
Macrophages are eliminated from the injured peripheral nerve via local apoptosis and circulation to regional lymph nodes and the spleen. J Neurosci (2001) 0.98
Apoptosis regulates the number of Schwann cells at the premyelinating stage. J Neurochem (1997) 0.92
Differential cyclin D1 requirements of proliferating Schwann cells during development and after injury. Mol Cell Neurosci (2001) 0.90
Nerve growth factor signaling of p75 induces differentiation and ceramide-mediated apoptosis in Schwann cells cultured from degenerating nerves. Glia (2001) 0.89
Leukemia inhibitory factor is an autocrine survival factor for Schwann cells. J Neurochem (1999) 0.88
Improved survival of injured sciatic nerve Schwann cells in mice lacking the p75 receptor. Neurosci Lett (1999) 0.88
Differentiation and apoptosis without DNA fragmentation in cultured Schwann cells derived from wallerian-degenerated nerve. Apoptosis (1998) 0.84
Schwann cell proliferation following lysolecithin-induced demyelination. J Neurocytol (1990) 0.83
Neurones and glial cells of the mouse sciatic nerve undergo apoptosis after injury in vivo and in vitro. Neuroreport (1995) 0.83
Mice lacking protease nexin-1 show delayed structural and functional recovery after sciatic nerve crush. J Neurosci (2007) 0.82
Rapid growth of regenerating axons across the segments of sciatic nerve devoid of Schwann cells. J Neurosci Res (1989) 0.81
A reassessment of the accuracy of reinnervation by motoneurons following crushing or freezing of the sciatic or lumbar spinal nerves of rats. Brain (1987) 0.81
Specific and nonspecific regeneration of motor axons after sciatic nerve injury and repair in the rat. J Neurol Sci (1987) 0.80
The effects of mitomycin C on remyelination in the peripheral nervous system. Nature (1974) 0.78
Mitomycin C induces a delayed and prolonged demyelination and conduction block due to Schwann cell destruction. Clin Exp Neurol (1990) 0.77
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res (2003) 8.06
Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol (2011) 6.67
Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature (2012) 5.23
Dissecting the genomic complexity underlying medulloblastoma. Nature (2012) 4.77
Mouse brain organization revealed through direct genome-scale TF expression analysis. Science (2004) 4.55
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol (2010) 4.48
Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance. Cell (2010) 4.37
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun (2011) 4.07
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol (2012) 3.88
Medulloblastomics: the end of the beginning. Nat Rev Cancer (2012) 3.01
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol (2013) 2.82
Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell (2010) 2.80
Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol (2011) 2.53
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet (2013) 2.42
Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol (2012) 2.34
Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers. Genes Dev (2004) 2.16
Progressive myoclonus in a child with a deep cerebellar mass. Neurology (2003) 2.16
Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci U S A (2005) 1.96
The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev (2008) 1.93
Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell (2009) 1.92
Activation of the mammalian target of rapamycin (mTOR) is essential for oligodendrocyte differentiation. J Neurosci (2009) 1.86
Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat Med (2010) 1.77
HDAC-mediated deacetylation of NF-κB is critical for Schwann cell myelination. Nat Neurosci (2011) 1.67
Ataxia and shaking in a 2-year-old girl: acute marijuana intoxication presenting as seizure. Pediatr Emerg Care (2005) 1.57
Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol (2014) 1.56
Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol (2012) 1.56
Microanatomy of axon/glial signaling during Wallerian degeneration. J Neurosci (2005) 1.46
Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol (2013) 1.43
Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J Clin Oncol (2011) 1.36
Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. Mol Cell Biol (2008) 1.36
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol (2013) 1.35
Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A (2013) 1.33
Medulloblastoma tumorigenesis diverges from cerebellar granule cell differentiation in patched heterozygous mice. Dev Biol (2003) 1.29
CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol (2014) 1.28
Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol (2004) 1.26
Soluble neuregulin-1 has bifunctional, concentration-dependent effects on Schwann cell myelination. J Neurosci (2010) 1.23
p38 MAPK activation promotes denervated Schwann cell phenotype and functions as a negative regulator of Schwann cell differentiation and myelination. J Neurosci (2012) 1.20
Focus on central nervous system neoplasia. Cancer Cell (2002) 1.18
INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J Neuropathol Exp Neurol (2005) 1.17
A novel syndrome caused by the E410K amino acid substitution in the neuronal β-tubulin isotype 3. Brain (2013) 1.15
Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor. J Neurooncol (2005) 1.13
Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol (2013) 1.12
UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53. Nat Med (2011) 1.12
miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol (2010) 1.10
Diencephalic syndrome: a cause of failure to thrive and a model of partial growth hormone resistance. Pediatrics (2005) 1.06
Stereotactic radiotherapy for localized low-grade gliomas in children: final results of a prospective trial. Int J Radiat Oncol Biol Phys (2005) 1.05
Intracerebral abscess in children: historical trends at Children's Hospital Boston. Pediatrics (2004) 1.03
High-resolution imaging demonstrates dynein-based vesicular transport of activated Trk receptors. J Neurobiol (2002) 1.02
Everyday cognitive function after craniopharyngioma in childhood. Pediatr Neurol (2006) 1.01
Overlay analysis of the oligonucleotide array gene expression profiles and copy number abnormalities as determined by array comparative genomic hybridization in medulloblastomas. Genes Chromosomes Cancer (2007) 0.99
Gain of 1q is a potential univariate negative prognostic marker for survival in medulloblastoma. Clin Cancer Res (2007) 0.98
Medulloblastoma outcome is adversely associated with overexpression of EEF1D, RPL30, and RPS20 on the long arm of chromosome 8. BMC Cancer (2006) 0.97
MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. Acta Neuropathol (2011) 0.96
E-cadherin expression in postnatal Schwann cells is regulated by the cAMP-dependent protein kinase a pathway. Glia (2008) 0.93
A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. Int J Radiat Oncol Biol Phys (2003) 0.92
Schwann cell preparation from single mouse embryos: analyses of neurofibromin function in Schwann cells. Methods Enzymol (2006) 0.90
Sleep dysfunction in long term survivors of craniopharyngioma. J Neurooncol (2012) 0.90
Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors. Cell Cycle (2012) 0.88
Soluble Neuregulin and Schwann Cell Myelination: a Therapeutic Potential for Improving Remyelination of Adult Axons. Mol Cell Pharmacol (2010) 0.87
Medulloblastomas and primitive neuroectodermal tumors rarely contain polyomavirus DNA sequences. Neuro Oncol (2002) 0.87
Dendritic alterations after dynamic axonal stretch injury in vitro. Exp Neurol (2010) 0.87
Magnetic resonance imaging of patched heterozygous and xenografted mouse brain tumors. J Neurooncol (2003) 0.86
Hedgehog-GLI pathway in medulloblastoma. J Clin Oncol (2012) 0.85
Neuropsychological functioning after surgery in children treated for brain tumor. Neurosurgery (2003) 0.85
A novel role for extracellular signal-regulated kinase 5 and myocyte enhancer factor 2 in medulloblastoma cell death. Cancer Res (2005) 0.84
Long-term clinical outcomes following treatment of childhood craniopharyngioma. Pediatr Blood Cancer (2010) 0.83
Marked regression of metastatic pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec): a case report and laboratory investigation. J Pediatr Hematol Oncol (2003) 0.82
α5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth. Acta Neuropathol (2013) 0.82
Cardiac risk after craniopharyngioma therapy. Pediatr Neurol (2008) 0.81
Pediatric brain tumors. Neurol Clin (2003) 0.80
Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastoma. Neuro Oncol (2010) 0.80
Craniopharyngioma therapy: long-term effects on hypothalamic function. Neurologist (2005) 0.79
WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol Commun (2014) 0.79
Posterior fossa ependymomas: a tale of two subtypes. Cancer Cell (2011) 0.79
First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development. J Biomed Nanotechnol (2016) 0.77
Introduction: survivors of childhood cancer: the new face of developmental disabilities. Dev Disabil Res Rev (2008) 0.77
Could α5-GABA-A receptor activation be used as a target for managing medulloblastomas? CNS Oncol (2014) 0.76
Molecular genetics of pediatric central nervous system tumors. Curr Oncol Rep (2006) 0.76
Medulloblastoma biology in the post-genomic era. Future Oncol (2012) 0.76
Molecular fingerprints of medulloblastoma and their application to clinical practice. Future Oncol (2011) 0.76
Inactivation of the tumor suppressor WTX in a subset of pediatric tumors. Genes Chromosomes Cancer (2013) 0.76
Pathologic intracellular signaling in childhood pilocytic astrocytomas. Neurology (2009) 0.75
Transverse myelitis after therapy for primitive neuroectodermal tumors. Pediatr Neurol (2006) 0.75
Application of microarrays to neurological disease. Arch Neurol (2003) 0.75
Medulloblastoma Subtypes Defined by Gene Expression Analysis 864. Neurosurgery (2006) 0.75
Growing spectrum and relevance of pediatric neuro-immunology. Curr Opin Pediatr (2010) 0.75
Recent advances in autism spectrum disorders. Curr Opin Pediatr (2011) 0.75
Sport-related concussion: time to take notice. Curr Opin Pediatr (2012) 0.75
Pediatric sleep medicine in 2008: state-of-the-art. Curr Opin Pediatr (2008) 0.75
Clinical practice guidelines and practice parameters for the child neurologist. J Child Neurol (2013) 0.75
Neuro-oncology training for the child neurology resident. Semin Pediatr Neurol (2011) 0.75